SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Expanding the clinical and genetic spectra of NKX6-2-related disorder.
|
29388673 |
2018 |
SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in NKX6-2 Cause Progressive Spastic Ataxia and Hypomyelination.
|
28575651 |
2017 |
SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Mutations in NKX6-2 Cause Progressive Spastic Ataxia and Hypomyelination.
|
28575651 |
2017 |
SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in NKX6-2 Cause Progressive Spastic Ataxia and Hypomyelination.
|
28575651 |
2017 |
SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
Mutations in NKX6-2 Cause Progressive Spastic Ataxia and Hypomyelination.
|
28575651 |
2017 |
SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
CNS myelin paranodes require Nkx6-2 homeoprotein transcriptional activity for normal structure.
|
15601927 |
2004 |
SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Leukodystrophy
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
Eleven new cases from eight families of different ethnic backgrounds carrying compound heterozygous and homozygous pathogenic variants in NKX6-2 were identified, evidencing a high NKX6-2 mutation burden in the hypomyelinating leukodystrophy disease spectrum.
|
31509304 |
2020 |
Leukodystrophy
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
We report on the identification of biallelic inactivating mutations in NKX6-2, a gene encoding a transcription factor regulating multiple developmental processes with a main role in oligodendrocyte differentiation and regulation of myelin-specific gene expression, as the cause underlying a previously unrecognized severe variant of hypomyelinating leukodystrophy.
|
28969374 |
2017 |
Leukodystrophy
|
0.120 |
Biomarker
|
disease |
HPO |
|
|
|
Nystagmus
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
NKX6-2 mutations should be considered in patients with autosomal recessive, very early onset of nystagmus, cerebellar ataxia with hypotonia that rapidly progresses to spasticity, particularly when associated with neuroimaging signs of hypomyelination.
|
31509304 |
2020 |
Seizures
|
0.110 |
AlteredExpression
|
phenotype |
BEFREE |
The phenotypic and neuroimaging expression in NKX6-2 is described and it is shown that phenotypes with epilepsy in the absence of overt hypomyelination and diffuse hypomyelination without seizures can occur.
|
31509304 |
2020 |
Nystagmus
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Seizures
|
0.110 |
Biomarker
|
phenotype |
HPO |
|
|
|
Ataxia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Dysarthria
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dystonia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hirsutism
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Muscle Spasticity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Scoliosis, unspecified
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Strabismus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hyperreflexia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Pyramidal sign
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cerebral atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Difficulty walking
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|